Clinical Trials
440
37 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2017
Active, not recruiting
12
2.7%
Completed
211
48.0%
Enrolling By Invitation
2
0.5%
Not yet recruiting
23
5.2%
Recruiting
57
12.9%
Terminated
14
3.2%
Unknown
105
23.9%
Withdrawn
16
3.6%
No approval data available
- Two major trials involving 4,232 participants found that Paxlovid does not reduce hospital admissions or deaths in vaccinated adults at higher risk of severe COVID-19, despite helping them recover faster. - The UK PANORAMIC trial showed median recovery time of 14 days with Paxlovid versus 21 days with usual care, while the Canadian CanTreatCOVID trial found recovery at 6 days versus 9 days respectively. - Hospitalization rates remained very low in both trials, with no statistically significant differences between Paxlovid and usual care groups across either study. - These findings provide crucial evidence for cost-effective targeting of Paxlovid treatment in today's highly vaccinated populations where severe COVID-19 outcomes are already rare.
- St. Michael's Hospital has commenced patient dosing in Arch Biopartners' Phase II trial evaluating LSALT peptide for preventing cardiac surgery-associated acute kidney injury (CS-AKI). - The international multicenter trial targets 240 patients and represents a potential first-in-class therapeutic approach for CS-AKI, which affects up to 30% of cardiac surgery patients. - LSALT peptide works by binding to the DPEP1 enzyme to inhibit organ inflammation, with previous Phase II results showing statistically significant reductions in inflammatory biomarkers. - The company is expanding trial sites to include U.S. centers while also advancing a separate Phase II trial of cilastatin for drug-induced acute kidney injury.
- Arch Biopartners received ethics approval for St. Michael's Hospital to join its Phase II trial evaluating LSALT peptide for preventing cardiac surgery-associated acute kidney injury. - The international trial targets 240 patients and represents a potential first-in-class therapeutic approach for CS-AKI, which affects up to 30% of cardiac surgery patients. - LSALT peptide works by binding to the DPEP1 enzyme to inhibit organ inflammation, with previous studies showing statistically significant reductions in inflammatory biomarkers. - St. Michael's Hospital will become the ninth site globally and fourth Canadian site in the multi-center, randomized, placebo-controlled study.
